Liver metastases and hepatocellular carcinomas are two of the most common causes of cancer deaths in the world.Radiofrequency ablation(RFA) is a well recognized,effective and minimally invasive means of treating malig...Liver metastases and hepatocellular carcinomas are two of the most common causes of cancer deaths in the world.Radiofrequency ablation(RFA) is a well recognized,effective and minimally invasive means of treating malignant hepatic tumors.This article describes the use of contrast-enhanced 3D ultrasound(CE-3DUS) in the staging,targeting and follow-up of patients with liver tumors undergoing RFA.In particular,its value in the management of large hepatic lesions will be illustrated.Current limitations of CE-3DUS and future developments in the technique will also be discussed.In summary,CE-3DUS is useful in the RFA of liver tumors with improved detection and display of occult lesions and recurrence,in the assessment of lesional geometry and orientation for a more accurate planning and guidance of multiple RFA needle electrodes in large tumors and in the evaluation of residual or recurrent disease within the immediate and/or subsequent follow-up periods.展开更多
Motive of the study is to present quantitative and qualitative analysis and comparison of beam data measurement with FF (flattening filter) and FFF (flattening filter free) beam in a Varian TrueBeam<sup>TM</s...Motive of the study is to present quantitative and qualitative analysis and comparison of beam data measurement with FF (flattening filter) and FFF (flattening filter free) beam in a Varian TrueBeam<sup>TM</sup> Medical Linear Accelerator. Critique of beam characterization and evolution of dosimetric properties for 6 MV, 10 MV, 15 MV FF beam and 6 MVFFF, 10 MVFFF FFF beam has been carried out. We performed the comparison of photon beam data for two standard FF photon energy 6 MV, 10 MV verses 6 MVFFF, and 10 MVFFF FFF beam. Determination and comparison of parameter involved PDD (Percentage depth dose), Depth dose profile, Symmetry, Flatness, Quality index, Relative output factor, Penumbra, Transmission factor, DLG (Dosimetric leaf gap), in addition to degree of Un-flatness and off-axis ratio of FFF beam. Outcomes of presenting study had shown that change of various parameters such as Percentage depth dose curves, Shape of the depth dose profile, Transmission, Value of quality index and significant rise in surface dose for FFF in comparison with FF beam. Differences in the output factor at lower and higher field sizes for FFF beam compared to that of FF beam were found. The maximum output factor deviation between 6 MV and 6 MVFFF was found to be 4.55%, whereas in 10 MV and 10 MVFFF was 5.71%. Beam quality TPR20/10 for FFF beam was found to be lesser in magnitude, 5.42% for 6 MVFFF whereas 4.50% for 10 MVFFF compared to 6 MV and 10 MV FF beam respectively. Jaw transmission and interleaf leakage for FFF beam were found to be lesser than FF beam. Also DLG for FFF beam was found to be lesser in magnitude comparable to that of flattened beam. This study is mainly inclined towards evaluation and comparison of the FF and FFF beam. It has been observed that, the outcome of a commissioning beam data generation fully complies with vendor specification and published literature.展开更多
BACKGROUND Sepsis is a severe clinical syndrome related to the host response to infection.The severity of infections is due to an activation cascade that will lead to an auto amplifying cytokine production:The cytokin...BACKGROUND Sepsis is a severe clinical syndrome related to the host response to infection.The severity of infections is due to an activation cascade that will lead to an auto amplifying cytokine production:The cytokine storm.Hemoadsorption by CytoSorb®therapy is a new technology that helps to address the cytokine storm and to regain control over various inflammatory conditions.AIM To evaluate prospectively CytoSorb®therapy used as an adjunctive therapy along with standard of care in septic patients admitted to intensive care unit(ICU).METHODS This was a prospective,real time,investigator initiated,observational multicenter study conducted in patients admitted to the ICU with sepsis and septic shock.The improvement of mean arterial pressure and reduction of vasopressor needs were evaluated as primary outcome.The change in laboratory parameters,sepsis scores[acute physiology and chronic health evaluation(APACHE II)and sequential organ failure assessment(SOFA)]and vital parameters were considered as secondary outcome.The outcomes were also evaluated in the survivor and nonsurvivor group.Descriptive statistics were used;a P value<0.05 was considered RESULTS Overall,45 patients aged≥18 and≤80 years were included;the majority were men(n=31;69.0%),with mean age 47.16±14.11 years.Post CytoSorb®therapy,26 patients survived and 3 patients were lost to follow-up.In the survivor group,the percentage dose reduction in vasopressor was norepinephrine(51.4%),epinephrine(69.4%)and vasopressin(13.9%).A reduction in interleukin-6 levels(52.3%)was observed in the survivor group.Platelet count improved to 30.1%(P=0.2938),and total lung capacity count significantly reduced by 33%(P<0.0001).Serum creatinine and serum lactate were reduced by 33.3%(P=0.0190)and 39.4%(P=0.0120),respectively.The mean APACHE II score was 25.46±2.91 and SOFA scores was 12.90±4.02 before initiation of CytoSorb®therapy,and they were reduced significantly post therapy(APACHE II 20.1±2.47;P<0.0001 and SOFA 9.04±3.00;P=0.0003)in the survivor group.The predicted mortality in our patient population before CytoSorb®therapy was 56.5%,and it was reduced to 48.8%(actual mortality)after CytoSorb®therapy.We reported 75%survival rate in patients given treatment in<24 h of ICU admission and 68%survival rates in patients given treatment within 24-48 h of ICU admission.In the survivor group,the average number of days spent in the ICU was 4.44±1.66 d;while in the nonsurvivor group,the average number of days spent in ICU was 8.5±15.9 d.CytoSorb®therapy was safe and well tolerated with no adverse events reported.CONCLUSION CytoSorb®might be an effective adjuvant therapy in stabilizing sepsis and septic shock patients.However,it is advisable to start the therapy at an early stage(preferably within 24 h after onset of septic shock).展开更多
The aim of this study is to investigate the possible risk factors of poor sleep quality among patients with type 2 diabetes mellitus on insulin therapy. The factors considered were age, sex, body mass index (BMI), gly...The aim of this study is to investigate the possible risk factors of poor sleep quality among patients with type 2 diabetes mellitus on insulin therapy. The factors considered were age, sex, body mass index (BMI), glycosylated haemoglobin (HbA1c), duration of diabetes and depression. A total of 202 diabetic patients aged 20 years or older were included in the study. The results showed that female sex and depression were independent risk factors for poor sleep quality among type 2 diabetics on insulin therapy. Findings may contribute to sleep disorder control in female patients with type 2 diabetes mellitus which has been linked to glycemic control.展开更多
CHARGE syndrome is a rare, recently well recognized entity with non-random pattern of congenital anomalies. The syndrome associations consist of C-coloboma of the eyes, H-heart disease, A-atresia of the choanae, R-ret...CHARGE syndrome is a rare, recently well recognized entity with non-random pattern of congenital anomalies. The syndrome associations consist of C-coloboma of the eyes, H-heart disease, A-atresia of the choanae, R-retarded growth and development, G-genital hypoplasia/genitourinary anomalies and E-ear anomalies and/or hearing loss. All anomalies are not seen in every case and a varied spectrum of associations is seen in most of the cases. The exact incidence is not known. However, the reported prevalence is approximately 1:10,000 births. We report one such case.展开更多
文摘Liver metastases and hepatocellular carcinomas are two of the most common causes of cancer deaths in the world.Radiofrequency ablation(RFA) is a well recognized,effective and minimally invasive means of treating malignant hepatic tumors.This article describes the use of contrast-enhanced 3D ultrasound(CE-3DUS) in the staging,targeting and follow-up of patients with liver tumors undergoing RFA.In particular,its value in the management of large hepatic lesions will be illustrated.Current limitations of CE-3DUS and future developments in the technique will also be discussed.In summary,CE-3DUS is useful in the RFA of liver tumors with improved detection and display of occult lesions and recurrence,in the assessment of lesional geometry and orientation for a more accurate planning and guidance of multiple RFA needle electrodes in large tumors and in the evaluation of residual or recurrent disease within the immediate and/or subsequent follow-up periods.
文摘Motive of the study is to present quantitative and qualitative analysis and comparison of beam data measurement with FF (flattening filter) and FFF (flattening filter free) beam in a Varian TrueBeam<sup>TM</sup> Medical Linear Accelerator. Critique of beam characterization and evolution of dosimetric properties for 6 MV, 10 MV, 15 MV FF beam and 6 MVFFF, 10 MVFFF FFF beam has been carried out. We performed the comparison of photon beam data for two standard FF photon energy 6 MV, 10 MV verses 6 MVFFF, and 10 MVFFF FFF beam. Determination and comparison of parameter involved PDD (Percentage depth dose), Depth dose profile, Symmetry, Flatness, Quality index, Relative output factor, Penumbra, Transmission factor, DLG (Dosimetric leaf gap), in addition to degree of Un-flatness and off-axis ratio of FFF beam. Outcomes of presenting study had shown that change of various parameters such as Percentage depth dose curves, Shape of the depth dose profile, Transmission, Value of quality index and significant rise in surface dose for FFF in comparison with FF beam. Differences in the output factor at lower and higher field sizes for FFF beam compared to that of FF beam were found. The maximum output factor deviation between 6 MV and 6 MVFFF was found to be 4.55%, whereas in 10 MV and 10 MVFFF was 5.71%. Beam quality TPR20/10 for FFF beam was found to be lesser in magnitude, 5.42% for 6 MVFFF whereas 4.50% for 10 MVFFF compared to 6 MV and 10 MV FF beam respectively. Jaw transmission and interleaf leakage for FFF beam were found to be lesser than FF beam. Also DLG for FFF beam was found to be lesser in magnitude comparable to that of flattened beam. This study is mainly inclined towards evaluation and comparison of the FF and FFF beam. It has been observed that, the outcome of a commissioning beam data generation fully complies with vendor specification and published literature.
文摘BACKGROUND Sepsis is a severe clinical syndrome related to the host response to infection.The severity of infections is due to an activation cascade that will lead to an auto amplifying cytokine production:The cytokine storm.Hemoadsorption by CytoSorb®therapy is a new technology that helps to address the cytokine storm and to regain control over various inflammatory conditions.AIM To evaluate prospectively CytoSorb®therapy used as an adjunctive therapy along with standard of care in septic patients admitted to intensive care unit(ICU).METHODS This was a prospective,real time,investigator initiated,observational multicenter study conducted in patients admitted to the ICU with sepsis and septic shock.The improvement of mean arterial pressure and reduction of vasopressor needs were evaluated as primary outcome.The change in laboratory parameters,sepsis scores[acute physiology and chronic health evaluation(APACHE II)and sequential organ failure assessment(SOFA)]and vital parameters were considered as secondary outcome.The outcomes were also evaluated in the survivor and nonsurvivor group.Descriptive statistics were used;a P value<0.05 was considered RESULTS Overall,45 patients aged≥18 and≤80 years were included;the majority were men(n=31;69.0%),with mean age 47.16±14.11 years.Post CytoSorb®therapy,26 patients survived and 3 patients were lost to follow-up.In the survivor group,the percentage dose reduction in vasopressor was norepinephrine(51.4%),epinephrine(69.4%)and vasopressin(13.9%).A reduction in interleukin-6 levels(52.3%)was observed in the survivor group.Platelet count improved to 30.1%(P=0.2938),and total lung capacity count significantly reduced by 33%(P<0.0001).Serum creatinine and serum lactate were reduced by 33.3%(P=0.0190)and 39.4%(P=0.0120),respectively.The mean APACHE II score was 25.46±2.91 and SOFA scores was 12.90±4.02 before initiation of CytoSorb®therapy,and they were reduced significantly post therapy(APACHE II 20.1±2.47;P<0.0001 and SOFA 9.04±3.00;P=0.0003)in the survivor group.The predicted mortality in our patient population before CytoSorb®therapy was 56.5%,and it was reduced to 48.8%(actual mortality)after CytoSorb®therapy.We reported 75%survival rate in patients given treatment in<24 h of ICU admission and 68%survival rates in patients given treatment within 24-48 h of ICU admission.In the survivor group,the average number of days spent in the ICU was 4.44±1.66 d;while in the nonsurvivor group,the average number of days spent in ICU was 8.5±15.9 d.CytoSorb®therapy was safe and well tolerated with no adverse events reported.CONCLUSION CytoSorb®might be an effective adjuvant therapy in stabilizing sepsis and septic shock patients.However,it is advisable to start the therapy at an early stage(preferably within 24 h after onset of septic shock).
文摘The aim of this study is to investigate the possible risk factors of poor sleep quality among patients with type 2 diabetes mellitus on insulin therapy. The factors considered were age, sex, body mass index (BMI), glycosylated haemoglobin (HbA1c), duration of diabetes and depression. A total of 202 diabetic patients aged 20 years or older were included in the study. The results showed that female sex and depression were independent risk factors for poor sleep quality among type 2 diabetics on insulin therapy. Findings may contribute to sleep disorder control in female patients with type 2 diabetes mellitus which has been linked to glycemic control.
文摘CHARGE syndrome is a rare, recently well recognized entity with non-random pattern of congenital anomalies. The syndrome associations consist of C-coloboma of the eyes, H-heart disease, A-atresia of the choanae, R-retarded growth and development, G-genital hypoplasia/genitourinary anomalies and E-ear anomalies and/or hearing loss. All anomalies are not seen in every case and a varied spectrum of associations is seen in most of the cases. The exact incidence is not known. However, the reported prevalence is approximately 1:10,000 births. We report one such case.
